Avalo Therapeutics, Inc. (AVTX)
NCM · Healthcare · Biotechnology
$14.76
+7.97%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$775.9M
Shares Outstanding
52.6M
P/S (TTM)
13,150x
Exchange
NCM
Currency
USD
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 59K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 59K | |
| Operating Income | -19.3M | -19.2M | -19.7M | -20.9M |
| Net Income | -20.8M | -30.6M | -13.7M | -19.6M |
| Diluted EPS | $-1.92 | $-2.19 | $nan | $-0.98 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 18.1M | 1.9M | 441K | 59K |
| Gross Profit | 14.6M | 640K | 807K | 59K |
| Operating Income | -37.4M | -23.4M | -40.9M | -72.9M |
| Net Income | -41.7M | -31.5M | -35.1M | -78.3M |
| Diluted EPS | $-1,063.20 | $-113.58 | $-20.91 | $nan |